Skip to main content
Explore URMC

URMC Logo

Julie Ryan, Ph.D., M.P.H.

Contact Information

Phone Numbers

Administrative: (585) 275-3871

Office: (585) 276-3862

Fax: (585) 273-1346

Biography

Julie L Ryan, PhD, MPH, is an Assistant Professor in the Departments of Dermatology and Radiation Oncology and a member of the Community Clinical Oncology Program (CCOP) Research Base at the University of Rochester Medical Center. She is a translational researcher combining the fields of cancer control, dermatology, and radiation oncology. She has expertise in cancer pathobiology, virology, and clinical research and trial design, with publications in lung cancer, breast cancer, gastric cancer, Epstein–Barr virus, and cancer treatment-related symptoms. The primary focus of Dr Ryan's research is cancer treatment symptom management, specifically radiation dermatitis and chemotherapy-related nausea.

Professional Background

Julie L Ryan, PhD, MPH, is an Assistant Professor in the Departments of Dermatology and Radiation Oncology and a member of the Community Clinical Oncology Program (CCOP) Research Base at the University of Rochester Medical Center. She is a translational researcher combining the fields of cancer control, dermatology, and radiation oncology. She has expertise in cancer pathobiology, virology, and clinical research and trial design, with publications in lung cancer, breast cancer, gastric cancer, Epstein–Barr virus, and cancer treatment-related symptoms. The primary focus of Dr Ryan's research is cancer treatment symptom management, specifically radiation dermatitis and chemotherapy-related nausea.

Research

Dr. Ryan performs basic and clinical research combining the fields of cancer control, dermatology, and radiation oncology. Dr. Ryan's research primarily focuses on uncovering the biological mechanisms of radiation-induced skin toxicities and developing a successful intervention to reduce these toxicities and improve the quality of life of cancer patients. Radiation dermatitis occurs in about 95% of patients and can negatively affect a patient's quality of life due to pain and premature interruption of radiation treatment. Management of radiation dermatitis has a broader significance as well; it has great importance in the morbidity and mortality expected in any potential "dirty bomb" attack. Curcumin, a component of turmeric, is a potent antioxidant and anti-inflammatory agent. It has been used for many years to treat skin ailments and is currently being used as an anti-cancer agent. Preclinical studies by our group demonstrated that curcumin (oral administration) reduced radiation skin toxicity by 50% in mice. Currently, Dr Ryan has preclinical laboratory studies and clinical trials examining the role of skin barrier dysfunction and reactive oxygen species (ROS) in the severity of radiation skin injury and testing the efficacy of curcumin (both oral and topical administration) as a mitigator of radiation skin injury. As part of the Center for Medical Countermeasures Against Radiation (U19) Program Grant, Dr Ryan is investigating the hypothesis that radiation-induced skin injury involves altered barrier function, haphazard dendritic cell trafficking, and reactive oxygen species (ROS)-mediated damage resulting in chronic inflammation and impeded wound healing. The clarification of the nature of these defects will provide a foundation for mitigating multi-organ damage from radiation. Furthermore, Dr. Ryan performs preclinical testing on other radioprotective/mitigative agents to reduce tissue injury while enhancing the sensitization of tumors to radiation. Additionally, Dr. Ryan is also interested in elucidating the potential physical and psychosocial factors that influence the frequency and severity of skin problems and pain experienced by cancer patients undergoing radiation treatment. She is currently performing a clinical study to test a new survey instrument designed to assess the skin problems and pain experienced by cancer patients undergoing radiation treatment. Besides radiation-induced skin injury, Dr. Ryan is also involved in studies examining ginger as an intervention for chemotherapy-related nausea. After a successful multisite clinical trial through the URCC Community Clinical Oncology Program (CCOP) demonstrated that ginger supplementation (i.e., capsules) significantly reduced acute chemotherapy-induced nausea in cancer patients receiving standard antiemetics during chemotherapy, Dr. Ryan has designed a pilot clinical trial to determine if ginger-scented nasal strips (Aromainhaler®) will be effective against chemotherapy-induced nausea.

Credentials

Faculty Appointments

Education

1997
B.A. in Biological Sciences | University of Chicago
Biology

2005
Ph.D., | University of North Carolina at Chapel Hill
Pathology

2007
Masters of Public Health-Clinical Investigation Track | University of Rochester School of Medicine & Dentistry

Awards

2007 - Present
Investigation New Drug (IND) #75,444 Curcumin C3 Complex, Food & Drug Administration
Sponsor: Center for Drug Evaluation and Res, Div of Drug Oncology Prod

2006 - 2010
National Institutes of Health Clinical Loan Repayment Program

2005 - 2007
National Cancer Institute Cancer Control Research Training Fellowship Award, Dept of Radiation Oncology
Sponsor: James P. Wilmot Cancer Ctr, Univ of Rochester Sch of Med & Dent

2005 - 2007
Rochester Clinical Research Fellow, Dept of Community and Preventative Medicine
Sponsor: University of Rochester School of Med & Dent

2004
Transportation Grant Award, Univ of North Carolina at Chapel Hill Graduate School
Sponsor: 11th Biennial Conf of Internat Assoc Res on Epstein-Barr Virus
Location: Regensberg, Germany

2004
Pathobiology of Cancer: The Edward A. Smuckler Memorial Workshop
Sponsor: American Association of Cancer Research
Location: Snowmass, CO

2002
American Society of Investigative Pathology Travel Award, Experimental Biology Meeting
Location: New Orleans, LA

2001 - 2005
Environmental Pathology Training Grant (#T32 ES07017)
Sponsor: University of North Carolina at Chapel Hill, Dept Path & Lab Med

VIEW ALL expand_more

Publications

Journal Articles

11/2016
Barlow ML, Cummings RJ, Pentland AP, Love TM, Haidaris CG, Ryan JL, Lord EM, Gerber SA. "Total-Body Irradiation Exacerbates Dissemination of Cutaneous Candida Albicans Infection." Radiation research.. 2016 Nov 0; 186(5):436-446. Epub 2016 Oct 06.

1/2015
Gerber SA, Cummings RJ, Judge JL, Barlow ML, Nanduri J, Johnson DE, Palis J, Pentland AP, Lord EM, Ryan JL. "Interleukin-12 preserves the cutaneous physical and immunological barrier after radiation exposure." Radiation research.. 2015 Jan 0; 183(1):72-81. Epub 2015 Jan 07.

7/2014
Gewandter JS, Mohile SG, Heckler CE, Ryan JL, Kirshner JJ, Flynn PJ, Hopkins JO, Morrow GR. "A phase III randomized, placebo-controlled study of topical amitriptyline and ketamine for chemotherapy-induced peripheral neuropathy (CIPN): a University of Rochester CCOP study of 462 cancer survivors." Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer.. 2014 Jul 0; 22(7):1807-14. Epub 2014 Feb 16.

Books & Chapters

2007
Chapter Title: Behavioral Interventions for Side Effects Related to Cancer and Cancer Treatments.
Book Title: Handbook of Behavioral Science and Cancer
Author List: Morrow, GR, Roscoe, JA, Mustian, KM, Hickok, JT, Ryan, JL, Matteson, S
Edited By: S. Miller
Published By: American Physchological Association2007

VIEW ALL PUBLICATIONS